Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Cervical Cancer

  Free Subscription


Articles published in Int J Cancer

Retrieve available abstracts of 71 articles:
HTML format
Text format



Single Articles


    October 2017
  1. MATSUZAKI S, Serada S, Hiramatsu K, Nojima S, et al
    Anti-glypican-1 antibody-drug conjugate exhibits potent preclinical antitumor activity against glypican-1 positive uterine cervical cancer.
    Int J Cancer. 2017 Oct 21. doi: 10.1002/ijc.31124.
    PubMed     Text format     Abstract available


  2. MATSUO K, Shimada M, Yamaguchi S, Kanao H, et al
    Identifying a candidate population for ovarian conservation in young women with clinical stage IB-IIB cervical cancer.
    Int J Cancer. 2017 Oct 4. doi: 10.1002/ijc.31084.
    PubMed     Text format     Abstract available


  3. PAN R, Zhu M, Yu C, Lv J, et al
    Cancer incidence and mortality: A cohort study in China, 2008-2013.
    Int J Cancer. 2017;141:1315-1323.
    PubMed     Text format     Abstract available


    September 2017
  4. ZHANG Q, Dong L, Hu S, Feng R, et al
    Risk stratification and long-term risk prediction of E6 oncoprotein in a prospective screening cohort in China.
    Int J Cancer. 2017;141:1110-1119.
    PubMed     Text format     Abstract available


    August 2017
  5. CLARKE MA, Luhn P, Gage JC, Bodelon C, et al
    Discovery and validation of candidate host DNA methylation markers for detection of cervical precancer and cancer.
    Int J Cancer. 2017;141:701-710.
    PubMed     Text format     Abstract available


  6. CHASIMPHA SJD, Parkin DM, Masamba L, Dzamalala CP, et al
    Three-year cancer incidence in Blantyre, Malawi (2008-2010).
    Int J Cancer. 2017;141:694-700.
    PubMed     Text format     Abstract available


  7. VELENTZIS LS, Caruana M, Simms KT, Lew JB, et al
    How will transitioning from cytology to HPV testing change the balance between the benefits and harms of cervical cancer screening? Estimates of the impact on cervical cancer, treatment rates and adverse obstetric outcomes in Australia, a high vaccina
    Int J Cancer. 2017 Aug 12. doi: 10.1002/ijc.30926.
    PubMed     Text format     Abstract available


    July 2017
  8. VACCARELLA S, Laversanne M, Ferlay J, Bray F, et al
    Cervical cancer in Africa, Latin America and the Caribbean, and Asia: Regional inequalities and changing trends.
    Int J Cancer. 2017 Jul 22. doi: 10.1002/ijc.30901.
    PubMed     Text format     Abstract available


  9. KHAN S, Oosterhuis K, Wunderlich K, Bunnik EM, et al
    Development of a replication-deficient adenoviral vector-based vaccine candidate for the interception of HPV16- and HPV18-induced infections and disease.
    Int J Cancer. 2017;141:393-404.
    PubMed     Text format     Abstract available


  10. BROTHERTON JM, Tabrizi SN, Phillips S, Pyman J, et al
    Looking beyond human papillomavirus (HPV) genotype 16 and 18: Defining HPV genotype distribution in cervical cancers in Australia prior to vaccination.
    Int J Cancer. 2017 Jul 5. doi: 10.1002/ijc.30871.
    PubMed     Text format     Abstract available


  11. MASSAD LS, Hessol NA, Darragh TM, Minkoff H, et al
    Cervical cancer incidence after up to 20 years of observation among women with HIV.
    Int J Cancer. 2017 Jul 3. doi: 10.1002/ijc.30866.
    PubMed     Text format     Abstract available


  12. VELDHUIJZEN NJ, Polman NJ, Snijders PJF, Meijer CJLM, et al
    Stratifying HPV-positive women for CIN3+ risk after one and two rounds of HPV-based screening.
    Int J Cancer. 2017 Jul 3. doi: 10.1002/ijc.30865.
    PubMed     Text format     Abstract available


    May 2017
  13. MATSUO K, Shimada M, Aoki Y, Sakamoto M, et al
    Comparison of adjuvant therapy for node-positive clinical stage IB-IIB cervical cancer: Systemic chemotherapy versus pelvic irradiation.
    Int J Cancer. 2017 May 19. doi: 10.1002/ijc.30793.
    PubMed     Text format     Abstract available


  14. LAM JU, Rebolj M, Moller Ejegod D, Pedersen H, et al
    Human papillomavirus self-sampling for screening nonattenders: Opt-in pilot implementation with electronic communication platforms.
    Int J Cancer. 2017;140:2212-2219.
    PubMed     Text format     Abstract available


  15. AGORASTOS T, Chatzistamatiou K, Moysiadis T, Kaufmann AM, et al
    Human papillomavirus E7 protein detection as a method of triage to colposcopy of HPV positive women, in comparison to genotyping and cytology. Final results of the PIPAVIR study.
    Int J Cancer. 2017 May 3. doi: 10.1002/ijc.30761.
    PubMed     Text format    


  16. SHEN C, Liu Y, Shi S, Zhang R, et al
    Long-distance interaction of the integrated HPV fragment with MYC gene and 8q24.22 region up-regulating the allele-specific MYC expression in HeLa cells.
    Int J Cancer. 2017 May 3. doi: 10.1002/ijc.30763.
    PubMed     Text format     Abstract available


  17. NICOLAS-PARRAGA S, Alemany L, de Sanjose S, Bosch FX, et al
    Differential HPV16 variant distribution in squamous cell carcinoma, adenocarcinoma and adenosquamous cell carcinoma.
    Int J Cancer. 2017;140:2092-2100.
    PubMed     Text format     Abstract available


    April 2017
  18. ROHNER E, Sengayi M, Goeieman B, Michelow P, et al
    Cervical Cancer Risk and Impact of Pap-based Screening in HIV-positive Women on Antiretroviral Therapy in Johannesburg, South Africa.
    Int J Cancer. 2017 Apr 25. doi: 10.1002/ijc.30749.
    PubMed     Text format     Abstract available


  19. BALTZER N, Sundstrom K, Nygard JF, Dillner J, et al
    Risk Stratification in Cervical Cancer Screening by Complete Screening History- Applying Bioinformatics to a General Screening Population.
    Int J Cancer. 2017 Apr 6. doi: 10.1002/ijc.30725.
    PubMed     Text format     Abstract available


  20. DE MARTEL C, Plummer M, Vignat J, Franceschi S, et al
    Worldwide burden of cancer attributable to HPV by site, country and HPV type.
    Int J Cancer. 2017 Apr 1. doi: 10.1002/ijc.30716.
    PubMed     Text format     Abstract available


    March 2017
  21. MEZEI AK, Armstrong HL, Pedersen HN, Campos NG, et al
    Cost-effectiveness of cervical cancer screening methods in low- and middle-income countries: a systematic review.
    Int J Cancer. 2017 Mar 15. doi: 10.1002/ijc.30695.
    PubMed     Text format     Abstract available


  22. HO D, Drake TK, Smith-McCune KK, Darragh TM, et al
    Feasibility of clinical detection of cervical dysplasia using angle-resolved low coherence interferometry measurements of depth-resolved nuclear morphology.
    Int J Cancer. 2017;140:1447-1456.
    PubMed     Text format     Abstract available


  23. DAS GHOSH D, Mukhopadhyay I, Bhattacharya A, Roy Chowdhury R, et al
    Impact of genetic variations and transcriptional alterations of HLA class I genes on cervical cancer pathogenesis.
    Int J Cancer. 2017 Mar 7. doi: 10.1002/ijc.30681.
    PubMed     Text format     Abstract available


    January 2017
  24. RODRIGUEZ AC, Avila C, Herrero R, Hildesheim A, et al
    Cervical cancer incidence after screening with HPV, cytology, and visual methods: 18-year follow-up of the Guanacaste cohort.
    Int J Cancer. 2017 Jan 24. doi: 10.1002/ijc.30614.
    PubMed     Text format     Abstract available


  25. POLMAN NJ, Uijterwaal MH, Witte BI, Berkhof J, et al
    Good performance of p16/ki-67 dual-stained cytology for surveillance of women treated for high-grade CIN.
    Int J Cancer. 2017;140:423-430.
    PubMed     Text format     Abstract available


    December 2016
  26. CHEN W, Molijn A, Enqi W, Zhang X, et al
    The variable clinicopathological categories and role of human papillomavirus in cervical adenocarcinoma: A hospital based nation-wide multi-center retrospective study across China.
    Int J Cancer. 2016;139:2687-2697.
    PubMed     Text format     Abstract available


  27. CAMPOS NG, Tsu V, Jeronimo J, Mvundura M, et al
    To Expand Coverage, or Increase Frequency: Quantifying the Tradeoffs between Equity and Efficiency Facing Cervical Cancer Screening Programs in Low-Resource Settings.
    Int J Cancer. 2016 Dec 7. doi: 10.1002/ijc.30551.
    PubMed     Text format     Abstract available


    November 2016
  28. KOCSIS A, Takacs T, Jeney C, Schaff Z, et al
    Performance of a New HPV and Biomarker Assay in Management of hrHPV Positive Women: Subanalysis of the Ongoing Multicenter TRACE Clinical Trial (n>6,000) to Evaluate POU4F3 as a Potential Biomarker of Cervical Precancer and Cancer.
    Int J Cancer. 2016 Nov 22. doi: 10.1002/ijc.30534.
    PubMed     Text format     Abstract available


  29. HABBEMA D, Weinmann S, Arbyn M, Kamineni A, et al
    Harms of Cervical Cancer Screening in the United States and the Netherlands.
    Int J Cancer. 2016 Nov 16. doi: 10.1002/ijc.30524.
    PubMed     Text format     Abstract available


    October 2016
  30. WU S, Wang S, Fu Y, Tang W, et al
    A novel mechanism of rs763110 polymorphism contributing to cervical cancer risk by affecting the binding affinity of CEBP/beta and OCT1 complex to chromatin.
    Int J Cancer. 2016 Oct 28. doi: 10.1002/ijc.30490.
    PubMed     Text format     Abstract available


  31. HOLT HK, Zhang L, Zhao FH, Hu SY, et al
    Evaluation of multiple primary and combination screening strategies in postmenopausal women for detection of cervical cancer in China.
    Int J Cancer. 2016 Oct 11. doi: 10.1002/ijc.30468.
    PubMed     Text format     Abstract available


  32. SCHIFFMAN M, Yu K, Zuna R, Terence Dunn S, et al
    Proof-of-principle study of a novel cervical screening and triage strategy: computer-analyzed cytology to decide which HPV-positive women are likely to have >/=CIN2.
    Int J Cancer. 2016 Oct 1. doi: 10.1002/ijc.30456.
    PubMed     Text format     Abstract available


    September 2016
  33. OGILVIE GS, Krajden M, van Niekerk D, Smith LW, et al
    HPV For Cervical cancer screening (HPV FOCAL): Complete Round 1 results of a randomized trial comparing HPV-based primary screening to liquid based cytology for cervical cancer.
    Int J Cancer. 2016 Sep 29. doi: 10.1002/ijc.30454.
    PubMed     Text format     Abstract available


  34. CASTANON A, Landy R, Sasieni PD
    Is cervical screening preventing adenocarcinoma and adenosquamous carcinoma of the cervix?
    Int J Cancer. 2016;139:1040-5.
    PubMed     Text format     Abstract available


    August 2016
  35. SIMMS KT, Smith MA, Lew JB, Kitchener HC, et al
    Will cervical screening remain cost-effective in women offered the next generation nonavalent HPV vaccine? Results for four developed countries.
    Int J Cancer. 2016 Aug 19. doi: 10.1002/ijc.30392.
    PubMed     Text format     Abstract available


  36. ISIDEAN SD, Mayrand MH, Ramanakumar AV, Gilbert L, et al
    Human Papillomavirus Testing versus Cytology in Primary Cervical Cancer Screening: End-of-Study and Extended Follow-Up Results from the Canadian Cervical Cancer Screening Trial (CCCaST).
    Int J Cancer. 2016 Aug 18. doi: 10.1002/ijc.30385.
    PubMed     Text format     Abstract available


  37. CAMPBELL C, Kafwafwa S, Brown H, Walker G, et al
    Use of thermo-coagulation as an alternative treatment modality in a 'screen-and-treat' programme of cervical screening in rural Malawi.
    Int J Cancer. 2016;139:908-15.
    PubMed     Text format     Abstract available


  38. SCHIFFMAN M, Hyun N, Raine-Bennett TR, Katki H, et al
    A Cohort Study of Cervical Screening Using Partial HPV Typing and Cytology Triage.
    Int J Cancer. 2016 Aug 10. doi: 10.1002/ijc.30375.
    PubMed     Text format     Abstract available


    June 2016
  39. DEPUYDT CE, Thys S, Beert J, Jonckheere J, et al
    Linear viral load increase of a single HPV-type in women with multiple HPV infections predicts progression to cervical cancer.
    Int J Cancer. 2016 Jun 24. doi: 10.1002/ijc.30238.
    PubMed     Text format     Abstract available


  40. ZHAO FH, Hu SY, Zhang Q, Zhang X, et al
    Risk assessment to guide cervical screening strategies in a large Chinese population.
    Int J Cancer. 2016;138:2639-47.
    PubMed     Text format     Abstract available


    May 2016
  41. CARLANDER C, Wagner P, Svedhem V, Elfgren K, et al
    Impact of immunosuppression and region of birth on risk of cervical intraepithelial neoplasia among migrants living with HIV in Sweden.
    Int J Cancer. 2016 May 13. doi: 10.1002/ijc.30188.
    PubMed     Text format     Abstract available


    April 2016
  42. TANG A, Dadaglio G, Oberkampf M, Di Carlo S, et al
    B cells promote tumor progression in a mouse model of HPV-mediated cervical cancer.
    Int J Cancer. 2016 Apr 30. doi: 10.1002/ijc.30169.
    PubMed     Text format     Abstract available


  43. RADDE K, Gottschalk A, Bussas U, Schulein S, et al
    Invitation to cervical cancer screening does increase participation in Germany: Results from the MARZY Study.
    Int J Cancer. 2016 Apr 15. doi: 10.1002/ijc.30146.
    PubMed     Text format     Abstract available


    March 2016
  44. EBISCH RM, de Kuyper-de Ridder GM, Bosgraaf RP, Massuger LF, et al
    The clinical value of HPV genotyping in triage of women with high-risk-HPV-positive self-samples.
    Int J Cancer. 2016 Mar 17. doi: 10.1002/ijc.30090.
    PubMed     Text format     Abstract available


    February 2016
  45. BROTHERTON JM, Jit M, Gravitt PE, Brisson M, et al
    Eurogin Roadmap 2015: How has HPV knowledge changed our practice: vaccines.
    Int J Cancer. 2016 Feb 24. doi: 10.1002/ijc.30063.
    PubMed     Text format     Abstract available


  46. HERWEIJER E, Sundstrom K, Ploner A, Uhnoo I, et al
    Quadrivalent HPV vaccine effectiveness against high-grade cervical lesions by age at vaccination: A population-based study.
    Int J Cancer. 2016 Feb 9. doi: 10.1002/ijc.30035.
    PubMed     Text format     Abstract available


  47. PETRY KU, Cox JT, Johnson K, Quint W, et al
    Evaluating HPV negative CIN2+ in the ATHENA trial.
    Int J Cancer. 2016 Feb 6. doi: 10.1002/ijc.30032.
    PubMed     Text format     Abstract available


  48. BHATIA R, Kavanagh K, Cubie H, Serrano I, et al
    Use of HPV testing for cervical screening in vaccinated women - insights from the SHEVa (Scottish HPV Prevalence in Vaccinated Women) study.
    Int J Cancer. 2016 Feb 4. doi: 10.1002/ijc.30030.
    PubMed     Text format     Abstract available


    January 2016
  49. MOLIJN A, Jenkins D, Chen W, Zhang X, et al
    The complex relationship between human papillomavirus and cervical adenocarcinoma.
    Int J Cancer. 2016;138:409-16.
    PubMed     Text format     Abstract available


  50. STENSEN S, Kjaer SK, Jensen SM, Frederiksen K, et al
    Factors associated with type-specific persistence of high-risk human papillomavirus infection: A population-based study.
    Int J Cancer. 2016;138:361-8.
    PubMed     Text format     Abstract available


  51. VAN BAARS R, van der Marel J, Snijders PJ, Rodriquez-Manfredi A, et al
    CADM1 and MAL methylation status in cervical scrapes is representative of the most severe underlying lesion in women with multiple cervical biopsies.
    Int J Cancer. 2016;138:463-71.
    PubMed     Text format     Abstract available


  52. SHEPPARD C, El-Zein M, Ramanakumar AV, Ferenczy A, et al
    Assessment of mediators of racial disparities in cervical cancer survival in the United States.
    Int J Cancer. 2016 Jan 12. doi: 10.1002/ijc.29996.
    PubMed     Text format     Abstract available


    December 2015
  53. SKINNER SR, Wheeler CM, Romanowski B, Castellsague X, et al
    Progression of HPV infection to detectable cervical lesions or clearance in adult women: Analysis of the control arm of the VIVIANE study.
    Int J Cancer. 2015 Dec 19. doi: 10.1002/ijc.29971.
    PubMed     Text format     Abstract available


  54. HOLL K, Nowakowski AM, Powell N, McCluggage WG, et al
    Human papillomavirus prevalence and type-distribution in cervical glandular neoplasias: Results from a European multinational epidemiological study.
    Int J Cancer. 2015;137:2858-68.
    PubMed     Text format     Abstract available


  55. HAMMER A, Rositch A, Qeadan F, Gravitt PE, et al
    Age-specific prevalence of HPV16/18 genotypes in cervical cancer: a systematic review and meta-analysis.
    Int J Cancer. 2015 Dec 13. doi: 10.1002/ijc.29959.
    PubMed     Text format     Abstract available


    November 2015
  56. CLIFFORD GM, Franceschi S, Keiser O, Schoni-Affolter F, et al
    Immunodeficiency and the risk of cervical intra-epithelial neoplasia 2/3 and cervical cancer: A nested case-control study in the Swiss HIV Cohort Study.
    Int J Cancer. 2015 Nov 4. doi: 10.1002/ijc.29913.
    PubMed     Text format     Abstract available


    September 2015
  57. VALDEZ M, Jeronimo J, Bansil P, Qiao YL, et al
    Effectiveness of novel, lower-cost molecular human papillomavirus-based tests for cervical cancer screening in rural China.
    Int J Cancer. 2015 Sep 30. doi: 10.1002/ijc.29877.
    PubMed     Text format     Abstract available


  58. ZHANG R, Shen C, Zhao L, Wang J, et al
    Dysregulation of host cellular genes targeted by HPV integration contributes to HPV related cervical carcinogenesis.
    Int J Cancer. 2015 Sep 29. doi: 10.1002/ijc.29872.
    PubMed     Text format     Abstract available


    August 2015
  59. LUTTMER R, De Strooper LM, Berkhof J, Snijders PJ, et al
    Comparing the performance of FAM19A4 methylation analysis, cytology and HPV16/18 genotyping for the detection of cervical (pre)cancer in high-risk HPV-positive women of a gynecologic outpatient population (COMETH study).
    Int J Cancer. 2015 Aug 28. doi: 10.1002/ijc.29824.
    PubMed     Text format     Abstract available


  60. CHUNG TK, Van Hummelen P, Chan PK, Cheung TH, et al
    Genomic aberrations in cervical adenocarcinomas in Hong Kong Chinese women.
    Int J Cancer. 2015;137:776-83.
    PubMed     Text format     Abstract available


    July 2015
  61. VACCARELLA S, Franceschi S, Bray F
    The incremental benefits of implementing effective cervical cancer screening.
    Int J Cancer. 2015 Jul 23. doi: 10.1002/ijc.29700.
    PubMed     Text format    


  62. HEIDENREICH R, Jasny E, Kowalczyk A, Lutz J, et al
    A novel RNA-based adjuvant combines strong immunostimulatory capacities with a favorable safety profile.
    Int J Cancer. 2015;137:372-84.
    PubMed     Text format     Abstract available


  63. THOMSEN LT, Frederiksen K, Munk C, Junge J, et al
    Long-term risk of cervical intraepithelial neoplasia grade 3 or worse according to high-risk human papillomavirus genotype and semi-quantitative viral load among 33,288 women with normal cervical cytology.
    Int J Cancer. 2015;137:193-203.
    PubMed     Text format     Abstract available


    June 2015
  64. ANTILL YC, Dowty JG, Ko Win A, Thompson T, et al
    Lynch Syndrome and Cervical Cancer.
    Int J Cancer. 2015 Jun 15. doi: 10.1002/ijc.29641.
    PubMed     Text format     Abstract available


  65. CUZICK J, Myers O, Hunt WC, Saslow D, et al
    Human papillomavirus testing 2007-2012: co-testing and triage utilization and impact on subsequent clinical management.
    Int J Cancer. 2015;136:2854-63.
    PubMed     Text format     Abstract available


  66. NAKAJIMA A, Endo H, Okuyama H, Kiyohara Y, et al
    Radiation sensitivity assay with a panel of patient-derived spheroids of small cell carcinoma of the cervix.
    Int J Cancer. 2015;136:2949-60.
    PubMed     Text format     Abstract available


  67. NGOMA T, Mandeli J, Holland JF
    Downstaging cancer in rural Africa.
    Int J Cancer. 2015;136:2875-9.
    PubMed     Text format     Abstract available


    May 2015
  68. HE Y, Lin J, Ding Y, Liu G, et al
    A systematic study on dysregulated microRNAs in cervical cancer development.
    Int J Cancer. 2015 May 27. doi: 10.1002/ijc.29618.
    PubMed     Text format     Abstract available


    March 2015
  69. OGILVIE GS, Naus M, Money DM, Dobson SR, et al
    Reduction in cervical dysplasia in young women in British Columbia after introduction of the HPV vaccine: An ecological analysis.
    Int J Cancer. 2015 Mar 6. doi: 10.1002/ijc.29508.
    PubMed     Text format     Abstract available


    January 2015
  70. VERDOODT F, Jiang X, Williams M, Schnatz PF, et al
    High-risk HPV testing in the management of atypical glandular cells: a systematic review and meta-analysis.
    Int J Cancer. 2015 Jan 12. doi: 10.1002/ijc.29424.
    PubMed     Text format     Abstract available


    October 2014
  71. UIJTERWAAL MH, Polman N, Witte BI, vanKemenade FJ, et al
    Full title: Triaging HPV-positive women with normal cytology by p16/Ki-67 dual-stained cytology testing: Baseline and longitudinal data.
    Int J Cancer. 2014 Oct 25. doi: 10.1002/ijc.29290.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Cervical Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: